Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2011

View Archived Issues

New phase IIa data presented on sifalimumab in systemic lupus erythematosus

Sunitinib has limited efficacy in advanced adrenocortical carcinoma in phase II trial

Scientists at Pfizer prepare novel phosphodiesterase 8B inhibitors

New tubulin inhibitors synthesized by R&D-Biopharmaceuticals

Plexxikon presents novel protein kinase inhibitors

Tekmira secures licenses to two validated oncology targets from Alnylam Pharmaceuticals

Incyte seeks FDA approval for ruxolitinib in myelofibrosis

First subject enrolled in phase II study of ALD-401 in ischemic stroke

Ipsen discontinues development of irosustat as monotherapy

GTx confirms phase III program design for ostarine in NSCLC

BAY-80-6946 is well tolerated in first-in-human trial in advanced solid tumors

VTX-2337 exhibits safety/tolerability in phase I trial in advanced solid tumors

Auspex Pharmaceuticals claims new antagonists of dopamine D2 and/or D3 receptor

Belgian scientists disclose new nicotinic acetylcholine receptor modulators

New PARP-1 inhibitor JI-1260 is a candidate for stroke therapy

Sound Pharmaceuticals begins trial of SPI-1005 for hearing loss induced by loud music

BioMarin begins phase III trial of amifampridine phosphate in LEMS

Oxygen Biotherapeutics gains approval to expand STOP-TBI to India

Nektar Therapeutics reports interim phase I data on NKTR-181

Biogen Idec receives European approval for Avonex Pen

BioMimetic Therapeutics completes enrollment in trial of Augment Rotator Cuff Graft

Johnson & Johnson begins phase II study of JNJ-40411813 in schizophrenia

Emergent BioSolutions acquires anticancer candidate zanolimumab from TenX BioPharma

Almirall launches Actikerall in U.K. for treatment of actinic keratosis

Bayer HealthCare submits MAA to EMA for VEGF Trap-Eye in wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...